Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 7
Submit an article Journal homepage
234
Views
2
CrossRef citations to date
0
Altmetric
Review

Computer Tools in the Discovery of HIV-1 Integrase Inhibitors

Chenzhong Liao1 Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, NCI-Frederick, 376 Boyles Street, Frederick, MD21702, USAView further author information
&
Marc C Nicklaus1 Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, NCI-Frederick, 376 Boyles Street, Frederick, MD21702, USACorrespondence[email protected]
View further author information
Pages 1123-1140 | Published online: 12 Jul 2010

Bibliography

  • Anthony NJ . HIV-1 integrase: a target for new AIDS chemotherapeutics.Curr. Top. Med. Chem.4(9), 979–990 (2004).
  • Bushman FD , FujiwaraT, CraigieR. Retroviral DNA integration directed by HIV integration protein in vitro. Science249(4976), 1555–1558 (1990).
  • Asante-Appiah E , SkalkaAM. HIV-1 integrase: structural organization, conformational changes, and catalysis.Adv. Virus. Res.52, 351–369 (1999).
  • Grobler JA , StillmockK, HuBet al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99(10), 6661–6666 (2002).
  • LaFemina RL , SchneiderCL, RobbinsHLet al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66(12), 7414–7419 (1992).
  • Egbertson MS . HIV integrase inhibitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM).Curr. Top. Med. Chem.7(13), 1251–1272 (2007).
  • Pace P , RowleyM. Integrase inhibitors for the treatment of HIV infection.Curr. Opin. Drug Discov. Devel.11(4), 471–479 (2008).
  • Marchand C , MaddaliK, MetifiotM, PommierY. HIV-1 IN inhibitors: 2010 update and perspectives.Curr. Top. Med. Chem.9(11), 1016–1037 (2009).
  • Al-Mawsawi LQ , Al-SafiRI, NeamatiN. Anti-infectives: clinical progress of HIV-1 integrase inhibitors.Expert Opin. Emerg. Drugs13(2), 213–225 (2008).
  • Anker M , CoralesRB. Raltegravir (MK-0518), a novel integrase inhibitor for the treatment of HIV infection.Expert Opin. Investig. Drugs17(1), 97–103 (2008).
  • Summa V , PetrocchiA, BonelliFet al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51(18), 5843–5855 (2008).
  • Sato M , MotomuraT, AramakiHet al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49(5), 1506–1508 (2006).
  • Shimura K , KodamaE, SakagamiYet al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82(2), 764–774 (2008).
  • Johns BA , SvoltoAC. Advances in two-metal chelation inhibitors of HIV integrase.Expert Opin. Ther. Pat18(11), 1225–1237 (2008).
  • Liao C , NicklausMC. Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study.ChemMedChem.5, 1053–1066 (2010).
  • Liao C , MarchandC, BurkeTR Jr et al. Authentic HIV-1 integrase inhibitors. Future Med. Chem.2(7), 1107–1122 (2010).
  • Young DC . Computational Drug Design: A Guide for Computational and Medicinal Chemists. John Wiley & Sons, Inc., NY, USA (2009).
  • Skjevik ÅA, Teigen K, Martinez A. Overview of computational methods employed in early-stage drug discovery. Future Med. Chem.1(1), 49–63 (2009).
  • Tanrikulu Y , SchneiderG. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening.Nat. Rev. Drug Discov.7(8), 667–677 (2008).
  • Tuccinardi T . Docking-based virtual screening: recent developments.Comb. Chem. High. Throughput Screen.12(3), 303–314 (2009).
  • Clark DE . What has computer-aided molecular design ever done for drug discovery?Expert Opin. Drug Discov.1(2), 103–110 (2006).
  • Schneider G , FechnerU. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov.4(8), 649–663 (2005).
  • Potemkin V , GrishinaM. Principles for 3D/4D QSAR classification of drugs.Drug Discov. Today13(21–22), 952–959 (2008).
  • Debnath AK . Quantitative structure–activity relationship (QSAR) paradigm–Hansch era to new millennium.Mini. Rev. Med. Chem.1(2), 187–195 (2001).
  • Nicklaus MC , NeamatiN, HongHet al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 40(6), 920–929 (1997).
  • Hong H , NeamatiN, WangSet al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 40(6), 930–936 (1997).
  • Neamati N , HongH, MazumderAet al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 40(6), 942–951 (1997).
  • Neamati N , HongH, SunderSet al. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 52(6), 1041–1055 (1997).
  • Hong H , NeamatiN, WinslowHEet al. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir. Chem. Chemother. 9(6), 461–472 (1998).
  • Mustata GI , BrigoA, BriggsJM. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.Bioorg. Med. Chem. Lett.14(6), 1447–1454 (2004).
  • Barreca ML , RaoA, De Luca L et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J. Chem. Inf. Comput. Sci.44(4), 1450–1455 (2004).
  • Barreca ML , FerroS, RaoAet al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48(22), 7084–7088 (2005).
  • Dayam R , SanchezT, ClementOet al. β-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem. 48(1), 111–120 (2005).
  • Dayam R , SanchezT, NeamatiN. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.J. Med. Chem.48(25), 8009–8015 (2005).
  • Deng J , SanchezT, Al-MawsawiLQet al. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorg. Med. Chem. 15(14), 4985–5002 (2007).
  • De Luca L , BarrecaML, FerroSet al. A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 18(9), 2891–2895 (2008).
  • Dayam R , Al-MawsawiLQ, ZawahirZet al. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J. Med. Chem. 51(5), 1136–1144 (2008).
  • Milne GW , NicklausMC, DriscollJSet al. National Cancer Institute drug information system 3D database. J. Chem. Inf. Comput. Sci. 34(5), 1219–1224 (1994).
  • Kawasuji T , YoshinagaT, SatoAet al. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg. Med. Chem. 14(24), 8430–8445 (2006).
  • Kawasuji T , FujiM, YoshinagaTet al. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 14(24), 8420–8429 (2006).
  • Hazuda DJ , AnthonyNJ, GomezRPet al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. 101(31), 11233–11238 (2004).
  • Jorgensen WL , Tirado-RivesJ. Molecular modeling of organic and biomolecular systems using BOSS and MCPRO.J. Comput. Chem.26(16), 1689–1700 (2005).
  • Carlson HA , MasukawaKM, RubinsKet al. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 43(11), 2100–2114 (2000).
  • Deng J , LeeKW, SanchezTet al. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J. Med. Chem. 48(5), 1496–1505 (2005).
  • Deng J , SanchezT, NeamatiN, BriggsJM. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.J. Med. Chem.49(5), 1684–1692 (2006).
  • Lins RD , BriggsJM, StraatsmaTPet al. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 76(6), 2999–3011 (1999).
  • Kier LB , HallLH. An electrotopological-state index for atoms in molecules.Pharm. Res.7(8), 801–807 (1990).
  • Rogers D , HopfingerAJ. Application of genetic function approximation to quantitative structure–activity relationships and quantitative structure-property relationships.J. Chem. Inf. Comput. Sci.34(4), 854–866 (2002).
  • Ponce YM . Total and local quadratic indices of the molecular pseudograph’s atom adjacency matrix: applications to the prediction of physical properties of organic compounds.Molecules8(9), 687–726 (2003).
  • Consonni V , TodeschiniR, PavanM. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors.J. Chem. Inf. Comput. Sci.42(3), 682–692 (2002).
  • Specht DF . Probabilistic neural networks.Neural Networks3(1), 109–118 (1990).
  • Cramer RD , PattersonDE, BunceJD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.J. Am. Chem. Soc.110(18), 5959–5967 (2002).
  • Klebe G , AbrahamU, MietznerT. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.J. Med. Chem.37(24), 4130–4146 (1994).
  • Ferguson AM , HeritageT, JonathonPet al. EVA: a new theoretically based molecular descriptor for use in QSAR/QSPR analysis. J. Comput. Aided Mol. Des. 11(2), 143–152 (1997).
  • Polanski J , WalczakB. The comparative molecular surface analysis (COMSA): a novel tool for molecular design.Comput. Chem.24(5), 615–625 (2000).
  • Goodford PJ . A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.J. Med. Chem.28(7), 849–857 (1985).
  • Baroni M , CostantinoG, CrucianiGet al. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct. Act. Relat. 12(1), 9–20 (1993).
  • Datar PA , KhedkarSA, MaldeAK, CoutinhoEC. Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands.J. Comput. Aided Mol. Des.20(6), 343–360 (2006).
  • Duca JS , HopfingerAJ. Estimation of molecular similarity based on 4D-QSAR analysis: formalism and validation.J. Chem. Inf. Comput. Sci.41(5), 1367–1387 (2001).
  • Raghavan K , BuolamwiniJK, FesenMRet al. Three-dimensional quantitative structure–activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. J Med. Chem. 38(6), 890–897 (1995).
  • Buolamwini JK , RaghavanK, FesenMRet al. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Pharm. Res. 13(12), 1892–1895 (1996).
  • Makhija MT , KulkarniVM. Eigen value analysis of HIV-1 integrase inhibitors.J. Chem. Inf. Comput. Sci.41(6), 1569–1577 (2001).
  • Buolamwini JK , AssefaH. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.J. Med. Chem.45(4), 841–852 (2002).
  • Makhija MT , KulkarniVM. QSAR of HIV-1 integrase inhibitors by genetic function approximation method.Bioorg. Med. Chem.10(5), 1483–1497 (2002).
  • Makhija MT , KulkarniVM. Molecular electrostatic potentials as input for the alignment of HIV-1 integrase inhibitors in 3D QSAR.J. Comput. Aided Mol. Des.15(11), 961–978 (2001).
  • Makhija MT , KulkarniVM. 3D-QSAR and molecular modeling of HIV-1 integrase inhibitors.J. Comput. Aided Mol. Des.16(3), 181–200 (2002).
  • Yuan H , ParrillAL. QSAR studies of HIV-1 integrase inhibition.Bioorg. Med. Chem.10(12), 4169–4183 (2002).
  • Costi R , SantoRD, ArticoMet al. 2,6-bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. 12(1), 199–215 (2004).
  • Makhija MT , KasliwalRT, KulkarniVM, NeamatiN. de novo design and synthesis of HIV-1 integrase inhibitors. Bioorg. Med. Chem.12(9), 2317–2333 (2004).
  • Kuo CL , AssefaH, KamathSet al. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J. Med. Chem. 47(2), 385–399 (2004).
  • Daeyaert FFD , VinkersHM, JongeMRDet al. Ligand–based computation of HIV-1 integrase inhibition strength within a series of b-ketoamide derivatives. internet electron. J. Mol. Des. 3(9), 528–543 (2004).
  • Marrero-Ponce Y . Linear indices of the “molecular pseudograph’s atom adjacency matrix”: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors.J. Chem. Inf. Comput. Sci.44(6), 2010–2026 (2004).
  • Di Santo R , CostiR, ArticoMet al. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco 60(5), 409–417 (2005).
  • Yuan H , ParrillA. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.J. Mol. Graph. Model.23(4), 317–328 (2005).
  • Nunthaboot N , TonmunpheanS, ParasukVet al. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem. 41(12), 1359–1372 (2006).
  • Niedbala H , PolanskiJ, GieleciakRet al. Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb. Chem. High. Throughput Screen. 9(10), 753–770 (2006).
  • Vilar S , SantanaL, UriarteE. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J. Med. Chem.49(3), 1118–1124 (2006).
  • Saiz-Urra L , GonzalezMP, FallY, GomezG. Quantitative structure–activity relationship studies of HIV-1 integrase inhibition. 1. GETAWAY descriptors.Eur. J. Med. Chem.42(1), 64–70 (2007).
  • Leonard JT , RoyK. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.Eur. J. Med. Chem.43(1), 81–92 (2008).
  • Iyer M , HopfingerAJ. Treating chemical diversity in QSAR analysis: modeling diverse HIV-1 integrase inhibitors using 4D fingerprints.J. Chem. Inf. Model.47(5), 1945–1960 (2007).
  • Dhaked DK , VermaJ, SaranA, CoutinhoEC. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).J. Mol. Model.15(3), 233–245 (2009).
  • Dessalew N . Investigation of the structural requirement for inhibiting HIV integrase: QSAR study.Acta. Pharm.59(1), 31–43 (2009).
  • de Melo EB , FerreiraMM. Multivariate QSAR study of 4,5-dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors.Eur. J. Med. Chem.44(9), 3577–3583 (2009).
  • Nikitin S , ZaitsevaN, DeminaOet al. A very large diversity space of synthetically accessible compounds for use with drug design programs. J. Comput. Aided Mol. Des. 19(1), 47–63 (2005).
  • Pommier Y , JohnsonAA, MarchandC. Integrase inhibitors to treat HIV/AIDS.Nat. Rev. Drug Discov.4(3), 236–248 (2005).
  • Heuer TS , BrownPO. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase–DNA complex.Biochemistry37(19), 6667–6678 (1998).
  • Dyda F , HickmanAB, JenkinsTMet al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266(5193), 1981–1986 (1994).
  • Lodi PJ , ErnstJA, KuszewskiJ, HickmanABet al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34(31), 9826–9833 (1995).
  • Bujacz G , JaskolskiM, AlexandratosJet al. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. J. Mol. Biol. 253(2), 333–346 (1995).
  • Chen JC , KrucinskiJ, MierckeLJet al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl Acad. Sci. USA 97(15), 8233–8238 (2000).
  • Gao K , ButlerSL, BushmanF. Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes.EMBO J.20(13), 3565–3576 (2001).
  • Wang JY , LingH, YangW, CraigieR. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein.EMBO J.20(24), 7333–7343 (2001).
  • Podtelezhnikov AA , GaoK, BushmanFD, McCammonJA. Modeling HIV-1 integrase complexes based on their hydrodynamic properties.Biopolymers68(1), 110–120 (2003).
  • Cai M , ZhengR, CaffreyMet al. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4(7), 567–577 (1997).
  • Goldgur Y , DydaF, HickmanABet al. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl Acad. Sci. USA 95(16), 9150–9154 (1998).
  • De Luca L , PedrettiA, VistoliGet al. Analysis of the full-length integrase–DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 310(4), 1083–1088 (2003).
  • De Luca L , VistoliG, PedrettiAet al. Molecular dynamics studies of the full-length integrase–DNA complex. Biochem. Biophys. Res. Commun. 336(4), 1010–1016 (2005).
  • Goldgur Y , CraigieR, CohenGHet al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96(23), 13040–13043 (1999).
  • Karki RG , TangY, BurkeTR Jr, Nicklaus MC. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J. Comput. Aided Mol. Des.18(12), 739–760 (2004).
  • Bujacz G , AlexandratosJ, WlodawerAet al. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 272(29), 18161–18168 (1997).
  • Wielens J , CrosbyIT, ChalmersDK. A three-dimensional model of the human immunodeficiency virus type 1 integration complex.J. Comput. Aided Mol. Des.19(5), 301–317 (2005).
  • Maignan S , GuilloteauJP, Zhou-LiuQet al. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 282(2), 359–368 (1998).
  • Davies DR , GoryshinIY, ReznikoffWS, RaymentI. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate.Science289(5476), 77–85 (2000).
  • Wang LD , LiuCL, ChenWZ, WangCX. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase–DNA complex.Biochem. Biophys. Res. Commun.337(1), 313–319 (2005).
  • Chen A , WeberIT, HarrisonRW, LeisJ. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends.J. Biol. Chem.281(7), 4173–4182 (2006).
  • Savarino A . In silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology4, 21 (2007).
  • Chen X , TsiangM, YuFet al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380(3), 504–519 (2008).
  • Ferro S , De LucaL, BarrecaMLet al. Docking studies on a new human immunodeficiency virus integrase–Mg–DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. J. Med. Chem.52(2), 569–573 (2009).
  • Barreca ML , IraciN, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem.4(9), 1446–1456 (2009).
  • Aishima J , GittiRK, NoahJEet al. A Hoogsteen base pair embedded in undistorted B-DNA. Nucleic Acids Res. 30(23), 5244–5252 (2002).
  • Liao C , NicklausMC. HIV-1 integrase–DNA models. In: HIV-1 Integrase: Mechanism and Inhibitor Design. John Wiley & Sons, Inc. (2010) (In Press).
  • Ren G , GaoK, BushmanFD, YeagerM. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA.J. Mol. Biol.366(1), 286–294 (2007).
  • Liao C , KarkiRG, MarchandC, PommierY, NicklausMC. Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA.Bioorg. Med. Chem. Lett.17(19), 5361–5365 (2007).
  • Di Santo R , CostiR, RouxAet al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 49(6), 1939–1945 (2006).
  • Barreca ML , IraciN, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem.4(9), 1446–1456 (2009).
  • Hazuda DJ , FelockP, WitmerMet al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453), 646–650 (2000).
  • Frisch MJ , TrucksGW, SchlegelHBet al. Gaussian 03, Revision E.01. Gaussian, Inc. Wallingford, CT, USA (2004).
  • Steiniger-White M , RaymentI, ReznikoffWS. Structure/function insights into Tn5 transposition.Curr. Opin. Struct. Biol.14(1), 50–57 (2004).
  • Flexner C . HIV drug development: the next 25 years.Nat. Rev. Drug Discov.6(12), 959–966 (2007).
  • Hare S , GuptaSS, ValkovE, EngelmanA, CherepanovP. Retroviral intasome assembly and inhibition of DNA strand transfer.Nature464(7286), 232–236 (2010).
  • Sitzmann M , FilippovIV, NicklausMC. Internet resources integrating many small-molecule databases.SAR QSAR Environ. Res.19(1–2), 1–9 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.